Patents by Inventor Xiaojing Wang

Xiaojing Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8119654
    Abstract: The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: February 21, 2012
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: Prakash Jagtap, Duy-Phong Pham-Huu, Frederick Cohen, Xiaojing Wang
  • Patent number: 8114856
    Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: February 14, 2012
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Xiaojing Wang, Michael T. Migawa, Richard H. Griffey
  • Publication number: 20120010191
    Abstract: Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: May 6, 2011
    Publication date: January 12, 2012
    Applicants: GENENTECH, INC., GILEAD CONNECTICUT, INC.
    Inventors: Antonio J.M. BARBOSA, Peter A. Blomgren, Kevin S. Currie, Ravi Krishnamoorthy, Jeffrey E. Kropf, Seung H. Lee, Scott A. Mitchell, Daniel Ortwine, Aaron C. Schmitt, Xiaojing Wang, Jianjun Xu, Wendy Young, Honglu Zhang, Zhongdong Zhao, Pavel E. Zhichkin
  • Publication number: 20110251176
    Abstract: Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is a thiazolyl, picolinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: April 6, 2011
    Publication date: October 13, 2011
    Inventor: Xiaojing Wang
  • Publication number: 20110245476
    Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Application
    Filed: March 9, 2011
    Publication date: October 6, 2011
    Applicant: ISIS Pharmaceuticals, Inc.
    Inventors: Michael T. Migawa, Xiaojing Wang, Eric E. Swayze, Richard H. Griffey
  • Publication number: 20110166334
    Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Application
    Filed: January 10, 2011
    Publication date: July 7, 2011
    Applicant: ISIS Pharmaceuticals,Inc.
    Inventors: Eric E. Swayze, Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Xiaojing Wang, Michael T. Migawa, Richard H. Griffey
  • Publication number: 20110118233
    Abstract: Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
    Type: Application
    Filed: May 6, 2009
    Publication date: May 19, 2011
    Inventors: Peter A. Blomgren, David R. Brittelli, Kevin S. Currie, Seung H. Lee, Jeffrey E. Kropf, Scott A. Mitchell, Aaron C. Schmitt, Xiaojing Wang, Jianjun Xu, Zhongdong Zhao, Pavel E. Zhichkin
  • Publication number: 20110059961
    Abstract: The invention relates to compounds of formula (I) which are useful as kinase inhibitors, more specifically useful as PIM kinase inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same, either alone or in combination, to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Application
    Filed: September 8, 2010
    Publication date: March 10, 2011
    Inventors: Xiaojing Wang, Allen J. Ebens, JR.
  • Patent number: 7893039
    Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: February 22, 2011
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Xiaojing Wang, Michael T. Migawa, Richard H. Griffey
  • Publication number: 20100261706
    Abstract: Provided herein are tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analogs and derivatives, compositions comprising an effective amount of a tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analog and/or derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, a reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, an ocular or opthalmologic disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, contrast induced nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of a tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analog or derivative.
    Type: Application
    Filed: December 8, 2009
    Publication date: October 14, 2010
    Applicant: INOTEK PHARMACEUTICALS CORPORATION
    Inventors: Prakash JAGTAP, Duy-Phong Pham-Huu, Frederick COHEN, Huiyong HU, Xiaojing WANG
  • Publication number: 20100121049
    Abstract: The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.
    Type: Application
    Filed: February 28, 2008
    Publication date: May 13, 2010
    Applicant: INOTEK PHARMACEUTICALS CORPORATION
    Inventors: Prakash Jagtap, Duy-Phong Pham-Huu, Frederick Cohen, Xiaojing Wang
  • Publication number: 20100004220
    Abstract: The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.
    Type: Application
    Filed: February 28, 2008
    Publication date: January 7, 2010
    Inventors: Prakash JAGTAP, Duy-Phong PHAM-HUU, Frederick COHEN, Xiaojing WANG
  • Publication number: 20080293649
    Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Application
    Filed: May 30, 2008
    Publication date: November 27, 2008
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Eric E. Swayze, Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Xiaojing Wang, Michael T. Migawa, Richard H. Griffey
  • Publication number: 20080214845
    Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Application
    Filed: February 29, 2008
    Publication date: September 4, 2008
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Michael T. Migawa, Xiaojing Wang, Eric Swayze, Richard H. Griffey
  • Publication number: 20060281763
    Abstract: Certain appropriately substituted forms of pyrimidine having a pyridylamine group at C-4 of the pyrimidine and an amide group on the pyridine ring are useful in the treatment of conditions associated with excessive TGF? activity.
    Type: Application
    Filed: March 27, 2006
    Publication date: December 14, 2006
    Inventors: Jonathan Axon, Sarvajit Chakravarty, Barry Hart, Glenn McEnroe, Alison Murphy, Karen Pontius, Peijue Sheng, Xiaojing Wang, Shanthi Yellapregada
  • Publication number: 20050256121
    Abstract: The present invention relates to new substituted five-membered compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Application
    Filed: March 30, 2005
    Publication date: November 17, 2005
    Applicant: Chiron Corporation
    Inventors: Anne Jefferson, Xiaodong Lin, Xiaojing Wang, Alice Rico, Annette Walter, Yasheen Zhou
  • Patent number: 6486158
    Abstract: [4,5]-Fused-3,6 disubstituted-pydidazines of Formula I are useful for inducing or promoting apoptosis and for arresting uncontrolled neoplastic cell proliferation, and are specifically useful in the arresting and treatment of neoplasia: wherein Y1 and Y2 are independently selected from the group consisting of (CH2)n,—C(X)—NH—,—(CH2)n—C(X)—O—, and X is O or S; R1 is selected from the group consisting of lower alkyl, lower alkenyl, lower alkynyl, and substituted or unsubstituted phenyl, pyridinyl, and the like; R2 is selected from the group consisting of substituted or unsubstituted phenyl, benzyl, pyridinyl, and the like; “A” is a benzene ring fused with the pyridazine ring; and R3 is independently selected in each instance form the group consisting of halogen, lower alkyl, and the like.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: November 26, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Xiaojing Wang, Gerhard Sperl, Paul Gross, Rifat Pamukcu, Gary A. Piazza
  • Publication number: 20020028936
    Abstract: 1,3-Disubstituted Indolin-2-Ones compounds are useful in the treatment of neoplasia.
    Type: Application
    Filed: September 28, 2001
    Publication date: March 7, 2002
    Inventors: Gerhard Sperl, Xiaojing Wang, Gary A. Piazza, Rifat Pamukcu
  • Patent number: 6180629
    Abstract: [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen-containing substituents in position one are useful for inducing or promoting apoptosis and for arresting uncontrolled neoplastic cell proliferation, and are specifically useful in the arresting and treatment of neoplasia, including precancerous and cancerous lesions.
    Type: Grant
    Filed: August 14, 1998
    Date of Patent: January 30, 2001
    Assignee: Cell Pathways, Inc.
    Inventors: Xiaojing Wang, Gerhard Sperl, Paul Gross, Rifat Pamukcu, Gary A. Piazza